Clinical Trial Update: Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nivolumab in combination with cabiralizumab for relapsed/refractory peripheral T cell lymphoma has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Cabiralizumab
• nivolumab (nivolumab)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Peripheral T Cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2021-09-10